SynthesisThe Cochrane database of systematic reviews2004
Tramadol for neuropathic pain.
Synthesis in The Cochrane database of systematic reviews, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05311774 (Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain), which is not on this map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Tramadol for neuropathic pain in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Interventions for treating pain and disability in adults with complex regional pain syndrome.The Cochrane database of systematic reviews · 2013Pooled it
- Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2006Pooled it
- Population Pharmacokinetic/Pharmacodynamic Modeling of O-Desmethyltramadol in Young and Elderly Healthy Volunteers.Drugs & aging · 2019Trial
- Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study.Clinical drug investigation · 2007Trial
- Burn Wound Healing: Clinical Complications, Medical Care, Treatment, and Dressing Types: The Current State of Knowledge for Clinical Practice.International journal of environmental research and public health · 2022Review
- TheTurkish journal of pharmaceutical sciences · 2020Article
- Article
- Tramadol differentially regulates M1 and M2 macrophages from human umbilical cord blood.Inflammopharmacology · 2017Article
- [Complex regional pain syndrome following distal fractures of the radius : Epidemiology, pathophysiological models, diagnostics and therapy].Der Unfallchirurg · 2016Review
- Neuropathic cancer pain: What we are dealing with? How to manage it?OncoTargets and therapy · 2014Review
- Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research.British journal of pharmacology · 2013Review
- [Pain management of burn injuries].Der Anaesthesist · 2011Review
- Evidence based guidelines for complex regional pain syndrome type 1.BMC neurology · 2010Article
- Malformations of the craniocervical junction (Chiari type I and syringomyelia: classification, diagnosis and treatment).BMC musculoskeletal disorders · 2009Review
- Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antinociceptive response in the presence of competitive antagonism: the interaction between tramadol and its active metabolite on micro-opioid agonism and monoamine reuptake inhibition, in the rat.Pharmaceutical research · 2008Article
- The role of tramadol in current treatment strategies for musculoskeletal pain.Therapeutics and clinical risk management · 2007Article
- Opioids for managing chronic non-malignant pain: safe and effective prescribing.Canadian family physician Medecin de famille canadien · 2006Review
- Combination analgesia in 2005 - a rational approach: focus on paracetamol-tramadol.Clinical rheumatology · 2006Review
- Tramadol sustained-release capsules : a viewpoint by Sergio Canavero and Vincenzo Bonicalzi.Drugs · 2006Article
Corrections and comments
- Updated by
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuropathic pain syndrome consists of a group of symptoms, including burning or shooting sensations, abnormal sensitivity to normally painless stimuli, or a greatly raised sensitivity to painful stimuli. A wide range of disorders can cause neuropathic pain, nerve damage being the only common factor.
objectivesWe aimed to review systematically the evidence from randomised controlled trials for the efficacy of tramadol in treating neuropathic pain. SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group trials register (July 2002), MEDLINE (January 1966 to July 2002), EMBASE (January 1980 to July 2002), and LILACS (January 1982 to July 2002) for randomised and quasi-randomised controlled trials. We also searched bibliographies of published trials. SELECTION CRITERIA: We included randomised and quasi-randomised controlled trials comparing tramadol with placebo, other pain relieving treatment, or no treatment in people of both sexes and all ages with neuropathic pain of all degrees of severity. DATA COLLECTION AND ANALYSIS: Two reviewers extracted data and scored trial quality. We calculated relative risks and numbers needed to treat for effectiveness and adverse effects. MAIN
resultsWe identified five eligible trials, three comparing tramadol with placebo, one comparing tramadol with clomipramine, and one comparing tramadol with morphine. All three trials comparing tramadol with placebo showed a significant reduction in neuropathic pain with tramadol. Two of the trials that compared tramadol to placebo (total 161 participants) were combined in a meta-analysis. The number needed to treat with tramadol compared to placebo to reach at least 50% pain relief was 3.5 (95% confidence interval 2.4 to 5.9). There were insufficient data to draw conclusions about the effectiveness of tramadol compared to either clomipramine or morphine. Only one trial considered subcategories of neuropathic pain. It found a significant therapeutic effect of tramadol on paraesthesiae, allodynia, and touch-evoked pain. Numbers needed to harm were calculated for side effects resulting in withdrawal from the placebo-controlled trials. Two trials provided these data, and the combined number needed to harm was 7.7 (95% confidence interval 4.6 to 20). REVIEWERS'
conclusionsTramadol is an effective treatment for neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.